Peanut Allergy Diagnosis in the Context of Grass Pollen Sensitization for 125 Patients: Roles of Peanut and Cross-Reactive Carbohydrate Determinants Specific IgE

2009 ◽  
Vol 149 (2) ◽  
pp. 91-97 ◽  
Author(s):  
L. Guilloux ◽  
M. Morisset ◽  
F. Codreanu ◽  
L. Parisot ◽  
D.A. Moneret-Vautrin
Keyword(s):  
Grass Pollen ◽  
Peanut Allergy ◽  
Specific Ige ◽  
Allergy Diagnosis

Peanut Allergy Diagnosis : Comparison of Three Commercial Specific IgE Assays

2006 ◽  
Vol 117 (2) ◽  
pp. S34
Author(s):  
H. Malandain ◽  
J.L. Fauquert ◽  
A. Tridon ◽  
H. Susini de Luca ◽  
S. Ughetto ◽  
...  
Keyword(s):  
Peanut Allergy ◽  
Specific Ige ◽  
Allergy Diagnosis

Utility of specific IgE to Ara h 6 in peanut allergy diagnosis

2015 ◽  
Vol 115 (2) ◽  
pp. 108-112 ◽  
Author(s):  
María Pedrosa ◽  
Teresa Boyano-Martínez ◽  
Carmen García-Ara ◽  
Teresa Caballero ◽  
Santiago Quirce
Keyword(s):  
Peanut Allergy ◽  
Specific Ige ◽  
Allergy Diagnosis ◽  
Ara H 6

Peanut allergy diagnosis: Moving from basic to more elegant testing

2020 ◽  
Vol 31 (4) ◽  
pp. 346-357 ◽  
Author(s):  
Aneta Krogulska ◽  
Robert A. Wood
Keyword(s):  
Peanut Allergy ◽  
Allergy Diagnosis

An evaluation of factors influencing response to epicutaneous immunotherapy for peanut allergy in the PEPITES trial

2020 ◽  
Vol 41 (5) ◽  
pp. 326-335 ◽  
Author(s):  
David M. Fleischer ◽  
Sharon Chinthrajah ◽  
Amy M. Scurlock ◽  
Dianne E. Campbell ◽  
Todd D. Green ◽  
...  
Keyword(s):  
Treatment Response ◽  
Peanut Allergy ◽  
Geometric Mean ◽  
Specific Ige ◽  
Double Blind ◽  
Treatment Benefit ◽  
Patch Application ◽  
Epicutaneous Immunotherapy ◽  
Lower Baseline ◽  
Baseline Characteristics

Background: Epicutaneous immunotherapy (EPIT) for peanut allergy is a potential novel immunotherapy that utilizes the unique cutaneous immunologic properties to induce desensitization. A randomized, double-blind, placebo-controlled Phase 3 trial (PEPITES) in peanut-allergic children 4‐11 years demonstrated an epicutaneous patch (DBV712) with 250 µg peanut protein was statistically superior to placebo in inducing desensitization following 12 months of daily treatment. Objective: To investigate what baseline and in-study factors influenced response to DBV712 250 µg, with a focus on patch adhesion, by posthoc analysis of PEPITES data. Methods: A posthoc multivariate model built with log-transformed Month 12 eliciting dose (ED) as the dependent variable was used to assess the influence of baseline characteristics and patch adhesion. Baseline characteristics and treatment response were also evaluated by stratifying subjects into decile subgroups by patch detachment rates over the 12-month study. Results: Multivariate analysis identified higher baseline ED and lower baseline peanut-specific IgE as the variables most predictive of higher Month 12 ED, followed by mean daily patch application duration, baseline SCORing Atopic Dermatitis (SCORAD) score, and age. By decile stratification, no association between patch detachment and treatment response was identified for 80% of DBV712-treated subjects. All DBV712-treated subjects, including those with the highest patch detachment rates, demonstrated treatment benefit measured by fold-changes in geometric mean ED. Conclusion: We identified subject baseline characteristics of higher baseline ED and lower baseline peanut-specific IgE as most predictive of higher Month 12 ED. For the majority of treated subjects, patch detachment did not impact treatment response. A minority of subjects, highly sensitive to peanut at baseline, had lower prespecified responder rates and higher patch detachment rates, yet still benefited from treatment based upon fold-changes in ED.

Increasing the accuracy of peanut allergy diagnosis by using Ara h 2

2012 ◽  
Vol 129 (4) ◽  
pp. 1056-1063 ◽  
Author(s):  
Thanh D. Dang ◽  
Mimi Tang ◽  
Sharon Choo ◽  
Paul V. Licciardi ◽  
Jennifer J. Koplin ◽  
...  
Keyword(s):  
Peanut Allergy ◽  
Allergy Diagnosis ◽  
Ara H 2
Sign in / Sign up

Export Citation Format

Share Document